Know Cancer

or
forgot password

Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion


Phase 4
18 Years
80 Years
Open (Enrolling)
Both
Pleural Effusion, Malignant

Thank you

Trial Information

Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion


Background: Chemical pleurodesis is the treatment of choice in most cases of malignant
pleural effusion. The literature mentions a variety of chemicals which may be used for this
purpose, each with its own advantages and disadvantages. The iodopovidone has been recently
studied due to the existence of some side effects of other agents. Nevertheless, there are
still some questions in the literature regarding its safety and possible adverse effects.
Because of these questions, we propose the development of a study to ensure the safety and
efficacy of iodopovidone as a pleurodesis sclerosing agent.

Objective: The main purpose of this study is to evaluate the safety of pleurodesis for
malignant pleural effusion using iodopovidone as a sclerosing agent in different doses. The
secondary objectives are to determine clinical efficacy and quality of life of the patients
after realization of the proposed procedure.

Methods: There will be a randomized clinical trial, covering patients diagnosed with
malignant pleural effusion at Hospital Aristides Maltez - Bahia League Against Cancer. The
research will be revised and approved by the Ethics in Research of the Heart Institute,
Hospital das ClĂ­nicas - FMUSP and of the Hospital Aristides Maltez - Bahia League Against
Cancer. The free and informed consent will be evaluated by the same authority pursuant and
the study group will include only those who agree to participate and signed an approved.
There will be included patients with malignant pleural effusion diagnosis. Main exclusion
criteira will be iodine allergie, renal failure, thyroid disease, refusal to sign the
informed consent and patients unable to respond the quality of life questionnaire. After
inclusion, patients will be randomized and assigned to two groups according to the
iodopovidone concentration solution: 1% or 2%. All procedures will be performed by infusion
of the solution through a chest tube previously placed.The data analysis will involve
clinical measures and complementary exams trying to evaluate all organ systems and sorting
through possible adverse effects, classifying those as CTCAEV. Clinical measures will
involve MRC dyspnea schedule, analogic visual pain schedule, visual acuity test, measurement
of pulse oximetry, heart rate, blood pressure and temperature. Complementary exams will be
chest x-ray, eletrocardiogram and laboratory tests. Such measures shall be performed in the
preoperative, immediate postoperative, second, fourth, eleventh and thirty days
postoperative. Quality of life questionnaires will be applied before and on thirty days
postoperative as well. After that, randomized groups will be compared.


Inclusion Criteria:



- malignant pleural effusion

- Recurrent pleural effusion

- Complete lung expansion (> 80%) after puncture emptying confirmed by chest
radiography.

- Karnofsky index > 40.

- Agreed to participate in the study and sign an Informed Consent

Exclusion Criteria:

- Thrombocytopenia or coagulation disorders

- Patients with impaired renal function

- Pleural or active systemic infection

- Massive neoplastic infiltration of the skin

- Inability to understand the quality of life questionnaire

- Previous pleural procedures

- Allergy to iodine

- Thyroid disorders

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Safety of iodopovidone as an agent for pleurodesis

Outcome Description:

The safety will be assessed by mean clinical measures as MRC dyspnea schedule, analogic visual pain schedule, visual acuity test, measurement of pulse oximetry, heart rate, blood pressure and temperature. Complementary exams will be chest x-ray, eletrocardiogram and laboratory tests.

Outcome Time Frame:

Until 30th day after surgical procedure

Safety Issue:

Yes

Principal Investigator

Ricardo M Terra, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

InCor Heart Institute

Authority:

Brazil: National Committee of Ethics in Research

Study ID:

GPPOT-02

NCT ID:

NCT01670786

Start Date:

January 2010

Completion Date:

July 2013

Related Keywords:

  • Pleural Effusion, Malignant
  • Pleural Effusion
  • Pleural Effusion, Malignant

Name

Location